[{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"}]